"Advanced recurrent non-small cell lung cancer remains an area of medical need. We are pleased to initiate this trial combining vantictumab, with its novel anti-cancer stem cell mechanism of action, with standard docetaxel chemotherapy and our preclinical studies have generated robust anti-tumor activity data for this combination," said Jakob Dupont, M.D., Chief Medical Officer of OncoMed. "From this trial we will learn more about the safety, biomarker effects, and potential efficacy of this novel Wnt pathway-targeting drug candidate in combination with chemotherapy in advanced NSCLC."
OncoMed recently initiated a Phase 1b study of vantictumab and paclitaxel in HER2 negative breast cancer. Interim results for the single-agent, first-in-human Phase 1a trial for vantictumab in solid tumor patients were reported at the European Cancer Congress (ECC) 2013 in Amsterdam, Netherlands in September 2013. Results from the Phase 1a study showed that vantictumab is well tolerated with early evidence of single agent activity. Additionally, clinical biomarker data from the Phase 1a trial indicating PD modulation of the Wnt pathway by vantictumab were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA in October 2013.
"OncoMed continues to execute on its clinical trial plans, initiating studies on a timely basis, partnering with top-tier oncology centers and generating encouraging new data," said Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer. "With the commencement of this trial of vantictumab in NSCLC, we have eleven trials actively enrolling patients across five distinctive therapeutic programs."
About Vantictumab (OMP-18R5)Vantictumab is a first-in-class antibody that has shown broad anti-CSC and anti-tumor activity in patient-derived xenograft tumor models. Vantictumab inhibits a key signaling pathway in cancer, the Wnt pathway. Specifically, vantictumab selectively targets Frizzled receptors, which are activators of Wnt signaling. Although vantictumab was originally identified by binding to Frizzled7, the antibody selectively targets five different Frizzled receptors. A Phase 1a trial for vantictumab is currently ongoing. Data from this clinical trial were presented at the European Cancer Conference (ECC 2013) in September 2013 in Amsterdam, NL. Biomarker data for this Phase 1a trial was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, in October 2013. Vantictumab is also being tested in combination with standard-of-care chemotherapy in a Phase 1b clinical trial in advanced NSCLC (vantictumab + docetaxel) and in a Phase 1b clinical trial in HER2 negative breast cancer (vantictumab + paclitaxel). An additional Phase1b trial is planned to start in 2013 with vantictumab in combination with standard-of-care chemotherapy in another distinct solid tumor indication. Vantictumab is part of OncoMed's collaboration with Bayer Pharma AG.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts